Open Internet by MindsNet

Limited access to non-US approved drugs in Western markets

Many high-quality drugs and biologics approved in non-US regions, such as South Korea, Japan, and China, do not make it to Western markets. The regulatory burden, lack of Western BD partners, IP issues, manufacturing, and commercial disinterest may be contributing factors. This results in potential treatments being inaccessible to patients in the US and EU.

Science, Medicine, Pharmacology